Research digest / questions
Tesamorelin: frequently asked questions, answered from the record.
Direct, cited answers on what tesamorelin is, how it works, what the trials measured, the safety record, and the approved-vs-off-label scope.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44), with a trans-3-hexenoic acid group on its N-terminus that resists DPP-IV cleavage [5]. It stimulates the body's own pulsatile growth hormone and raises IGF-1 [4]. It is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy.
What does tesamorelin do?
It binds the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth hormone secretion and hepatic IGF-1 production, which together promote lipolysis preferentially in visceral abdominal fat [1][4]. It is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy; all other uses are off-label.
How does tesamorelin work?
It activates the Gs/adenylyl-cyclase/cAMP/PKA cascade at the GHRH receptor, driving GH gene transcription and pulsatile GH release; GH then stimulates hepatic IGF-1 [4]. In healthy men, 2 mg/day for two weeks raised mean overnight GH and increased IGF-1 by 181 ug/L [4].
Will tesamorelin help me lose belly fat?
In HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% over 26 weeks (placebo +5.0%) [1]. Efficacy is established in HIV-associated lipodystrophy; general-population fat loss is off-label and not established by large RCTs. This describes research findings, not a recommendation.
How long does it take to see fat loss from tesamorelin?
In the pivotal trials, significant visceral-fat reduction was measured at 26 weeks and sustained through 52 weeks of continued dosing (about -18% at one year) [1][2]. These are study timelines in the HIV population, not individual guidance.
Does tesamorelin burn belly fat?
It selectively reduces visceral abdominal fat in studies, generally without changing subcutaneous fat or BMI: a 2026 meta-analysis of five RCTs reported visceral adipose tissue -27.71 cm2 versus control [3]. The mechanism is GH/IGF-1-driven lipolysis, studied in HIV-associated lipodystrophy.
Is tesamorelin a growth hormone?
No. Tesamorelin is not growth hormone; it is a GHRH analogue that prompts the pituitary to release the body's own GH in its natural pulsatile rhythm, rather than supplying exogenous GH [4].
Does tesamorelin work for fat loss in non-HIV users?
Pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy [1]. A mechanistic study in healthy men showed expected GH/IGF-1 effects [4], but no large general-population fat-loss RCT has been completed, so non-HIV efficacy is mechanistically plausible but not established. Such use is off-label.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
In a 6-month JAMA RCT of HIV patients, tesamorelin reduced hepatic lipid by a net -2.9% [6]. NAFLD/MASLD use is investigational and off-label; the approved indication remains HIV-associated lipodystrophy visceral fat.
How does tesamorelin affect the liver in NAFLD?
By reducing visceral fat and raising GH/IGF-1, it lowers hepatic fat: the JAMA HIV trial showed a net -2.9% reduction in liver lipid-to-water percentage [6]. A secondary NAFLD analysis linked lower hepatic IGF-1 expression to greater steatosis and worse glycemia [9]. This is studied in HIV-associated fatty liver, where the approved fat-reduction indication applies.
Can tesamorelin reduce liver fat?
In studies of HIV patients, yes: a JAMA RCT reported a net -2.9% reduction in hepatic fat [6], and a 2026 meta-analysis of five RCTs reported hepatic fat fraction -4.28% [3]. Liver-fat reduction outside HIV-associated lipodystrophy is investigational.
What is the half-life of tesamorelin?
Plasma exposure is short. Population PK modeling reported apparent clearance of about 1,060 L/h; secondary sources (FDA label, Mayo Clinic) describe a terminal half-life on the order of 26-38 minutes [10]. Despite rapid clearance, downstream IGF-1 elevation persists across the dosing interval.
How long does tesamorelin stay in your system?
The peptide clears the plasma rapidly (terminal half-life ~26-38 minutes per secondary sources; clearance ~1,060 L/h in population PK) [10]. Its biological effect outlasts plasma presence because the resulting GH pulse sustains elevated IGF-1 across the once-daily interval.
What are the side effects of tesamorelin?
Reported effects include injection-site reactions and growth-hormone-class effects such as arthralgia and fluid retention. The prescribing label lists contraindications including active malignancy, hypersensitivity, and pregnancy, with warnings about stimulating GH and raising IGF-1 [5][7]. The LiverTox monograph classifies it as an unlikely cause of liver injury (likelihood score E) [5].
Who should not take tesamorelin?
Per the prescribing label, tesamorelin is contraindicated in active malignancy (treatment must be complete and the malignancy inactive), known hypersensitivity to tesamorelin or excipients, and pregnancy [7]. These are labeled regulatory facts, not personal medical advice.
Does tesamorelin increase the risk of diabetes or affect blood sugar?
A dedicated 12-week randomized placebo-controlled trial in people with type 2 diabetes found tesamorelin (1 or 2 mg/day) did not significantly alter fasting glucose, HbA1c, or insulin response versus placebo; total and non-HDL cholesterol fell in the 2 mg group [7]. In healthy men, neither fasting glucose nor insulin-stimulated glucose uptake changed significantly [4]. Monitoring is still warranted in dysglycemia.
Is tesamorelin FDA approved?
Yes, but narrowly: tesamorelin was approved in 2010 (NDA 022505) only to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. Every other use, including general or cosmetic fat loss, anti-aging, and performance, is off-label and not FDA-approved.
Does tesamorelin raise IGF-1 levels?
Yes. By stimulating endogenous GH, it raises hepatic IGF-1: the pivotal HIV trial reported IGF-1 +81.0% [1], a healthy-men study reported IGF-1 +181 ug/L over two weeks at 2 mg/day [4], and an early dose-ranging trial reported dose-related IGF-1 increases (+48% at 1 mg, +65% at 2 mg) [8].
How does tesamorelin stimulate growth hormone release?
It binds the GHRH receptor, a Gs-coupled receptor on pituitary somatotrophs, raising cAMP via adenylyl cyclase and activating PKA, which drives GH gene transcription and granule exocytosis [4]. Its DPP-IV-resistant N-terminal modification extends activity relative to native GHRH, and PK-PD modeling confirms it stimulates GH in an episodic, pulsatile manner [10].
What happens when you stop taking tesamorelin?
In the 52-week program, visceral fat reaccumulated upon discontinuation: the benefit is contingent on continued dosing [2]. The studied effect is not a permanent body-composition change.
Is tesamorelin safe for women?
The pivotal HIV-lipodystrophy trials enrolled both men and women [1]. Pregnancy is a labeled contraindication: animal organogenesis studies showed hydrocephaly in offspring [7]. These are research and regulatory findings, not dosing guidance.
Does tesamorelin cause water retention?
Fluid-related effects such as edema and arthralgia are recognized growth-hormone-class effects of raising GH and IGF-1. In the controlled trials adverse events were generally mild; the type-2-diabetes safety trial reported mild adverse events and no serious events [7], and the early dose-ranging trial described tesamorelin as generally well tolerated [8].